- Trials with a EudraCT protocol (86)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)

These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006). | |
Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records. |
Study title: Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N−demethylation. Jones DR, Gorski JC, Haehner BD, O’Mara EM Jr, Hall SD. Clinical pharmacology and therapeutics, Oct 1996, vol. 60, no. 4, p. 374−84. |
Active substance: ERYTHROMYCIN |
Study summary document link (including results): |
View full study record |
Document reference: 26456 |
Study title: Aleksa K et al Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide Nephrotoxicity Pediatr Nephrol. 2005 Jul;20(7):872-85. Epub 2005 May 4Aleksa K et al Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide Nephrotoxicity Pediatr Nephrol. 2005 Jul;20(7):872-85. Epub 2005 May 4 |
Active substance: CYCLOPHOSPHAMIDE |
Study summary document link (including results): |
View full study record |
Document reference: 24718 |
Study title: Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Clinical pharmacology and therapeutics, Oct 2005, vol. 78, no. 4, p. 400−11Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Clinical pharmacology and therapeutics, Oct 2005, vol. 78, no. 4, p. 400−11 |
Active substance: TIZANIDINE |
Study summary document link (including results): |
View full study record |
Document reference: 38507 |
Study title: Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. |
Active substance: TINZANIDINE |
Study summary document link (including results): |
View full study record |
Document reference: 44787 |
Study title: Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Clinical pharmacology and therapeutics, Oct 2005, vol. 78, no. 4, p. 400−11Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Clinical pharmacology and therapeutics, Oct 2005, vol. 78, no. 4, p. 400−11 |
Active substance: TINZANIDINE |
Study summary document link (including results): |
View full study record |
Document reference: 44791 |
Study title: Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Clinical pharmacology and therapeutics, Oct 2005, vol. 78, no. 4, p. 400−11Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Clinical pharmacology and therapeutics, Oct 2005, vol. 78, no. 4, p. 400−11 |
Active substance: TINZANIDINE |
Study summary document link (including results): |
View full study record |
Document reference: 44803 |